{"analyses":[{"ciLowerLimit":"0.000","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.369","estimateComment":"Confidence interval estimated using the Clopper Pearson method.","groupIds":["OG000"],"nonInferiorityComment":"Estimation only.","nonInferiorityType":"OTHER","paramType":"Overall Response Rate","paramValue":"0"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Overall response will be determined as the best treatment response for each patient as a binary variable indicating whether or not the patient achieved a Complete Response (CR) or Partial Response (PR) as determined by RECIST v1.1 criteria. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1):Complete Response (CR) is the disappearance of all lesions (target and non target); Partial Response (PR) is at least 30% decrease in the sum of the diameters of target lesions from baseline and no new lesions or unequivocal progression in non target lesions from baseline; Stable Disease (SD) is neither sufficient shrinkage in target lesions to qualify for PR (less than 30% decrease) nor sufficient increase in target lesions (versus smallest sum of diameters) to qualify for PD (less than 20% increase), with no new lesions or unequivocal progression in non target lesions from baseline. For the purposes of response determination, confirmatory scan for CR and PR is required.","groups":[{"description":"This group contains all subjects enrolled on the study, who received crizotinib, pooling the subjects in the three molecularly defined cohorts.","id":"OG000","title":"Total Enrolled Study Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Study was designed to evaluate objective response rate overall for all enrolled subjects and not separately by molecular cohorts. Efficacy analyses were conducted on the population of subjects who began crizotinib treatment. Analysis of overall response rate was conducted on those patients in the efficacy population with measurable disease present at baseline.","reportingStatus":"POSTED","timeFrame":"From enrollment to best response while on crizotinib; Subjects remained on treatment until disease progression or death or unacceptable toxicity (subjects were on treatment for an average of 6 weeks)","title":"Overall Response","type":"PRIMARY","unitOfMeasure":"Participants"}